CHF121.18 Novartis (NOVN.SW) SIX after-hours 08 Apr 2026: most active, analyst signals

NOVN.SW stock closed CHF121.18 in after-hours trading on the SIX exchange on 08 Apr 2026, down 1.64% on the day with volume at 3,324,703.00 shares. Traders flagged Novartis AG (NOVN.SW) among the most active Swiss healthcare names after a busy session. We summarise price drivers, valuation, and short-term technicals, then compare Meyka AI model forecasts to today’s price. Meyka AI’s data-driven view helps frame potential entry points and risks for investors focused on Swiss healthcare exposure.

Price action and intraday drivers for NOVN.SW stock

Novartis (NOVN.SW) traded between CHF120.54 and CHF123.42 during the session and opened at CHF123.40. The share price closed after hours at CHF121.18, a CHF2.02 decline versus the prior close of CHF123.20. Volume was 3,324,703.00 versus an average volume of 3,375,987.00, keeping NOVN.SW among the most active names on SIX.

One clear driver is fund positioning: recent Bloomberg ETF and fund reports show Novartis as a top holding in large Europe and dividend ETFs, supporting liquidity and active trading in the stock. See related holdings in Bloomberg fund listings for context Bloomberg – JPMECAU holdings and Bloomberg – VIGI holdings.

Fundamentals and valuation snapshot for NOVN.SW stock

Novartis reports EPS 5.70 and a current P/E of 21.02, versus a healthcare sector average P/E near 29.44. Market cap stands at approximately CHF228.60B. The company pays a trailing dividend of CHF3.01 per share, a yield near 2.01%.

Key ratios show higher price-to-book at 6.23 and debt-to-equity at 0.80, above the sector average debt of 0.66, while return on equity is a strong 32.80%. That mix points to premium valuation on some metrics, offset by above-average profitability and cash flow strength.

Technicals and trading signals for most active NOVN.SW stock

Short-term indicators show neutral momentum: RSI at 46.24, MACD histogram slightly positive at 0.31, and ADX 21.69, indicating a weak trend. Bollinger mid is CHF120.22 with a band range CHF115.49–124.95, implying current price sits inside the band near the median.

Volume and pattern context: on relative volume of 0.80, trading was active but not extreme. Traders watching NOVN.SW stock may use a break above CHF124.00 for momentum confirmation, or look to CHF115.50 as a lower technical support area.

Meyka AI grade and model forecast for NOVN.SW stock

Meyka AI rates NOVN.SW with a score out of 100: 73.91 | Grade B+ | Suggestion: BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors.

Meyka AI’s forecast model projects monthly CHF111.91 (implied -7.65% vs CHF121.18), quarterly CHF138.03 (implied +13.91%), and yearly CHF121.57 (implied +0.32%). Longer-term model outputs are CHF150.28 in 3 years (+24.01%) and CHF178.74 in 5 years (+47.50%). Forecasts are model-based projections and not guarantees.

Earnings calendar, catalysts and risks for NOVN.SW stock

Novartis has an earnings announcement scheduled for 28 Apr 2026. Upcoming catalysts include quarterly results, regulatory updates on pipeline programs, and Sandoz margin commentary. Positive surprises may trigger re-rating given current PE of 21.02.

Key risks include pricing pressure in generics, R&D setbacks, and higher leverage relative to some peers. Watch net income trends and free cash flow per share of 8.76, which supports the dividend and buyback optionality.

Sector context and portfolio fit for NOVN.SW stock

Novartis sits in the Healthcare sector on SIX in Switzerland, where average P/E is 29.44 and average ROE is 18.88%. NOVN.SW’s ROE of 32.80% outperforms peers, making it attractive for investors seeking profitability inside defensive healthcare exposure.

For allocation, consider NOVN.SW stock for dividend and core pharma exposure, while balancing with higher-growth biotech positions. See Novartis company page for market data and liquidity Novartis on Meyka.

Final Thoughts

NOVN.SW stock remains one of the most active Swiss healthcare names after hours on 08 Apr 2026, trading at CHF121.18 on SIX with volume 3,324,703.00. Valuation sits at a P/E 21.02, below the sector average, while ROE 32.80% and free cash flow per share 8.76 show clear operational strength. Meyka AI’s grade of B+ (73.91) reflects this mix of profitability and premium metrics. Our forecast model shows near-term divergence: a monthly target CHF111.91 (-7.65%) and a quarterly target CHF138.03 (+13.91%), with a one-year projection near CHF121.57 (+0.32%). Traders should watch the 28 Apr 2026 earnings date and movement above CHF124.00 for momentum confirmation. Remember that model forecasts are projections, not guarantees. For active traders, NOVN.SW’s liquidity and institutional holdings make it suitable for tactical ideas, while long-term investors should weigh valuation versus cash flow and pipeline risks.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.